Retina Synthesis

147 Folgen

1. 18 Month Results of the Derby and Oaks Trials for Treatment of Geographic Atrophy

   Vom: 4.8.2022
2. A Novel Retinal Sealant

   Vom: 28.7.2022
3. New Developments in Imaging and Therapy of Sickle Cell Retinopathy

   Vom: 21.7.2022
4. High Dose (8mg) Aflibercept for Treatment of Neovascular AMD

   Vom: 7.7.2022
5. New Developments in the Management of Choroidal Melanoma

   Vom: 30.6.2022
6. A Stem Cell Implant for the Treatment of Geographic Atrophy

   Vom: 23.6.2022
7. DERBY and OAKS Results

   Vom: 16.6.2022
8. Artificial Intelligence in the Management of Macular Degeneration

   Vom: 9.6.2022
9. An Oral Agent for the Treatment of Diabetic Retinopathy

   Vom: 2.6.2022
10. Home OCT Monitoring of Neovascular AMD Treatment

    Vom: 26.5.2022
11. Faricimab in Diabetic Macular Edema: 2 Year Results of the RHINE and YOSEMITE studies

    Vom: 19.5.2022
12. The Kingfisher Trial of Brolucizumab for DME

    Vom: 12.5.2022
13. Subretinal Fluid in Neovascular AMD: Friend or Foe?

    Vom: 5.5.2022
14. Optogenetics

    Vom: 28.4.2022
15. Inhibition of Plasma Kallikrein in Diabetic Macular Edema

    Vom: 21.4.2022
16. Neovascular AMD: Unpacking Surgical Disease Management Options

    Vom: 14.4.2022
17. Ocular Therapeutics Sustained Release TKI Trial

    Vom: 7.4.2022
18. Gene Therapy of nAMD and Diabetic Retinopathy with Dr. Allen Ho

    Vom: 31.3.2022
19. Long Term Results of the Port Delivery System

    Vom: 24.3.2022
20. The Altissimo Study using a TKI for nAMD

    Vom: 17.3.2022